HLA-A*02:01 restriction
Some T-cell-receptor drugs only work in people with a particular immune 'tissue type'. About half of people of European ancestry have it; far fewer in some other populations.
Tebentafusp, brenetafusp, and afamitresgene autoleucel recognise peptides presented on HLA-A*02:01, so eligibility requires a blood test. Frequencies vary from ~45-50% in Europeans to under 20% in some African and East Asian populations, creating an equity problem that next-generation TCR agents against other alleles aim to address.
Pages like this
not linked directly; found by shared links- Targetgp100 (PMEL)
Shares Tebentafusp, Uveal melanoma, Antigen presentation & immune editing, TCR-T cell therapy.
- CompanyImmunocore
Shares Brenetafusp, Tebentafusp, PRAME, Uveal melanoma.
- TrialPRISM-MEL-301
Shares Brenetafusp, PRAME, T-cell engagers (bispecific), Melanoma.
- TargetMAGE-A4
Shares Afamitresgene autoleucel, Antigen presentation & immune editing, TCR-T cell therapy, Sarcomas (soft tissue, bone, GIST).
- CompanyImmatics
Shares PRAME, TCR-T cell therapy, Sarcomas (soft tissue, bone, GIST), Melanoma.
- IdeaExtending sarcoma TCR-T beyond HLA-A*02
Shares Afamitresgene autoleucel, TCR-T cell therapy, Sarcomas (soft tissue, bone, GIST).
- TrialIMCgp100-202
Shares Tebentafusp, T-cell engagers (bispecific), Melanoma.
- Key paperSPEARHEAD-1: afami-cel, the first engineered T-cell receptor therapy approved for a solid tumour, in synovial sarcoma
Shares Afamitresgene autoleucel, TCR-T cell therapy, Sarcomas (soft tissue, bone, GIST).